プログラム - congre.co.jp

1 23 9:30 10:30 JSTAR 10:30 11:50 JMOG 12:00 13:00 1 LS1 Addressing the risk of localized STS of the extremities and retroperitoneum: present perspectives and future of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milan Alessandro Gronchi 13:25 13:30 13:30 16:00 Multidisciplinary Discussion MD-1 MD-2 MD-3 MD-4 MD-5 MD-6 16:15 17:15 1 SS1 For Better Treatment of Soft Tissue Sarcoma (STS).

2 Learnings from the Experts in the Foreign CountriesDivision of Medical Oncology, National Cancer Centre, Senior Consultant/Deputy Head, Singapore Richard Hong Hui Quek Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong Herbert HF Loong Department of Oncology, National Taiwan University Hospital, Taiwan Tom Wei-Wu Chen 17:30 18:30 2 SS2 Delvelopments in treatment of soft tissue sarcomaDepartment of Medicine, Sarcoma Service Memorial Sloan Kettering Cancer Center William D Tap 24 8:30 9:30 MS Development of novel targeted therapy for synovial sarcoma: present and future 9:45 11:00 1 SP1-1 SP1-2 SP1-3 /iPS 11:15 12.

3 45 SP2-1 SP2-2 NY-ESO-1 SP2-3 SP2-4 13:05 14:05 2 LS2 STS Treatment Update Now and FutureSarcoma Unit, Royal Marsden Hospital and Sarcoma Clinical Trials, The Institute of Cancer Research, London, UK Robin L. Jones 14:10 14:40 JSTAR 14:50 17.

4 20 JSTAR Sarcoma Conference JSTAR JSTAR Sarcoma Conference Sarcoma Multi-Disciplinary Team conference JSTAR NCCH NEST Nagoya End Sarcoma Team 17:20 17:35 1.

5 TR P1-1 RNA sequence p53 P1-2 AKT P1-3 IDH1/IDH2 Developmental and Stem Cell Biology, Hospital for Sick Children, Toronto ON, Canada P1-4 IDH P1-5 microRNA-25-3p P1-6 Ewing-like sarcoma P1-7 EPHB4 T P1-8 Ewing EWS-FLI1 FOXQ1 P1-9 RNA P1-10 microRNA P1-11 P1-12 ASPL-TFE3

6 P1-13 CIC-DUX4 2. P2-1 Deep Learning AI P2-2 P2-3 P2-4 1 P2-5 PEComa P2-6 P2-7 P2-8 (HOPES008) 3. P3-1 NY-ESO-1 TCR T P3-2 Pazopanib P3-3 P3-4 P3-5 P3-6 3 P3-7 Gemcitabine Docetaxel P3-8 P3-9 A retrospective analysis of efficacy and safety of olaratumab + doxorubicin or doxorubicin alone

7 In patients with uterine Developmet Unit-Japan Oncology, Eli Lilly Japan Tajimi Masaomi P3-10 P3-11 P3-12 P3-13 Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft tissue sarcomaDepartment of Medical Oncology, Cancer Institute Hospital of the Japanese Foundation for Cancer Research Nakano Kenji P3-14 P3-15 GEM DTX P3-16 + P3-17 4.

8 P4-1 Malignant wound P4-2 P4-3 P4-4 P4-5 20 P4-6 CT navigation(iCT) P4-7 P4-8 P4-9 P4-10 unplanned excision P4-11 IMRT P4-12 5.

9 P5-1 AYA P5-2 (BNCT) P5-3 P5-4 P5-5 P5-6 The Sarcoma Policy Checklist - focusing policy efforts on sarcomaMedicines Developmet Unit-Japan Oncology, Eli Lilly Japan Drove Nora P5-7 GISTERS NPO GISTERS P5-8 10 P5-9 P5-10 1.

10 TR A1-1 Eribulin mesilate A1-2 DCBLD2 A1-3 A1-4 A1-5 A1-6 RNA A1-7 T A1-8 DNA A1-9 2.